Antioxidants for Alzheimer disease: A randomized clinical trial with cerebrospinal fluid biomarker measures

Douglas R. Galasko, Elaine Peskind, Christopher M. Clark, Joseph Quinn, John M. Ringman, Gregory A. Jicha, Carl Cotman, Barbara Cottrell, Thomas J. Montine, Ronald G. Thomas, Paul Aisen

Research output: Contribution to journalArticle

188 Citations (Scopus)

Abstract

Objective: To evaluate whether antioxidant supplements presumed to target specific cellular compartments affected cerebrospinal fluid (CSF) biomarkers. Design: Double-blind, placebo-controlled clinical trial. Setting: Academic medical centers. Participants: Subjects with mild to moderate Alzheimer disease. Intervention: Random assignment to treatment for 16 weeks with 800 IU/d of vitamin E (α-tocopherol) plus 500 mg/d of vitamin C plus 900 mg/d of α-lipoic acid (E/C/ALA); 400 mg of coenzyme Q 3 times/d; or placebo. Main Outcome Measures: Changes from baseline to 16 weeks in CSF biomarkers related to Alzheimer disease and oxidative stress, cognition (Mini-Mental State Examination), and function (Alzheimer's Disease Cooperative Study Activities of Daily Living Scale). Results: Seventy-eight subjects were randomized; 66 provided serial CSF specimens adequate for biochemical analyses. Study drugs were well tolerated, but accelerated decline in Mini-Mental State Examination scores occurred in the E/C/ALA group, a potential safety concern. Changes in CSF Aβ42, tau, and P-tau181 levels did not differ between the 3 groups. Cerebrospinal fluid F2-isoprostane levels, an oxidative stress biomarker, decreased on average by 19% from baseline to week 16 in the E/C/ALA group but were unchanged in the other groups. Conclusions: Antioxidants did not influence CSF biomarkers related to amyloid or tau pathology. Lowering of CSF F2-isoprostane levels in the E/C/ALA group suggests reduction of oxidative stress in the brain. However, this treatment raised the caution of faster cognitive decline, which would need careful assessment if longer-term clinical trials are conducted. Trial Registration: clinicaltrials.gov Identifier: NCT00117403.

Original languageEnglish (US)
Pages (from-to)836-841
Number of pages6
JournalArchives of Neurology
Volume69
Issue number7
DOIs
StatePublished - Jul 2012

Fingerprint

Cerebrospinal Fluid
Alzheimer Disease
Randomized Controlled Trials
Antioxidants
Biomarkers
F2-Isoprostanes
Oxidative Stress
Placebos
Thioctic Acid
Dilatation and Curettage
Ubiquinone
Tocopherols
Needs Assessment
Controlled Clinical Trials
Activities of Daily Living
Clinical Trials
Alzheimer's Disease
Vitamin E
Amyloid
Vitamins

ASJC Scopus subject areas

  • Clinical Neurology
  • Arts and Humanities (miscellaneous)

Cite this

Antioxidants for Alzheimer disease : A randomized clinical trial with cerebrospinal fluid biomarker measures. / Galasko, Douglas R.; Peskind, Elaine; Clark, Christopher M.; Quinn, Joseph; Ringman, John M.; Jicha, Gregory A.; Cotman, Carl; Cottrell, Barbara; Montine, Thomas J.; Thomas, Ronald G.; Aisen, Paul.

In: Archives of Neurology, Vol. 69, No. 7, 07.2012, p. 836-841.

Research output: Contribution to journalArticle

Galasko, DR, Peskind, E, Clark, CM, Quinn, J, Ringman, JM, Jicha, GA, Cotman, C, Cottrell, B, Montine, TJ, Thomas, RG & Aisen, P 2012, 'Antioxidants for Alzheimer disease: A randomized clinical trial with cerebrospinal fluid biomarker measures', Archives of Neurology, vol. 69, no. 7, pp. 836-841. https://doi.org/10.1001/archneurol.2012.85
Galasko, Douglas R. ; Peskind, Elaine ; Clark, Christopher M. ; Quinn, Joseph ; Ringman, John M. ; Jicha, Gregory A. ; Cotman, Carl ; Cottrell, Barbara ; Montine, Thomas J. ; Thomas, Ronald G. ; Aisen, Paul. / Antioxidants for Alzheimer disease : A randomized clinical trial with cerebrospinal fluid biomarker measures. In: Archives of Neurology. 2012 ; Vol. 69, No. 7. pp. 836-841.
@article{3a7efd56a7d64b40aa1f46af0ce5f6c6,
title = "Antioxidants for Alzheimer disease: A randomized clinical trial with cerebrospinal fluid biomarker measures",
abstract = "Objective: To evaluate whether antioxidant supplements presumed to target specific cellular compartments affected cerebrospinal fluid (CSF) biomarkers. Design: Double-blind, placebo-controlled clinical trial. Setting: Academic medical centers. Participants: Subjects with mild to moderate Alzheimer disease. Intervention: Random assignment to treatment for 16 weeks with 800 IU/d of vitamin E (α-tocopherol) plus 500 mg/d of vitamin C plus 900 mg/d of α-lipoic acid (E/C/ALA); 400 mg of coenzyme Q 3 times/d; or placebo. Main Outcome Measures: Changes from baseline to 16 weeks in CSF biomarkers related to Alzheimer disease and oxidative stress, cognition (Mini-Mental State Examination), and function (Alzheimer's Disease Cooperative Study Activities of Daily Living Scale). Results: Seventy-eight subjects were randomized; 66 provided serial CSF specimens adequate for biochemical analyses. Study drugs were well tolerated, but accelerated decline in Mini-Mental State Examination scores occurred in the E/C/ALA group, a potential safety concern. Changes in CSF Aβ42, tau, and P-tau181 levels did not differ between the 3 groups. Cerebrospinal fluid F2-isoprostane levels, an oxidative stress biomarker, decreased on average by 19{\%} from baseline to week 16 in the E/C/ALA group but were unchanged in the other groups. Conclusions: Antioxidants did not influence CSF biomarkers related to amyloid or tau pathology. Lowering of CSF F2-isoprostane levels in the E/C/ALA group suggests reduction of oxidative stress in the brain. However, this treatment raised the caution of faster cognitive decline, which would need careful assessment if longer-term clinical trials are conducted. Trial Registration: clinicaltrials.gov Identifier: NCT00117403.",
author = "Galasko, {Douglas R.} and Elaine Peskind and Clark, {Christopher M.} and Joseph Quinn and Ringman, {John M.} and Jicha, {Gregory A.} and Carl Cotman and Barbara Cottrell and Montine, {Thomas J.} and Thomas, {Ronald G.} and Paul Aisen",
year = "2012",
month = "7",
doi = "10.1001/archneurol.2012.85",
language = "English (US)",
volume = "69",
pages = "836--841",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "7",

}

TY - JOUR

T1 - Antioxidants for Alzheimer disease

T2 - A randomized clinical trial with cerebrospinal fluid biomarker measures

AU - Galasko, Douglas R.

AU - Peskind, Elaine

AU - Clark, Christopher M.

AU - Quinn, Joseph

AU - Ringman, John M.

AU - Jicha, Gregory A.

AU - Cotman, Carl

AU - Cottrell, Barbara

AU - Montine, Thomas J.

AU - Thomas, Ronald G.

AU - Aisen, Paul

PY - 2012/7

Y1 - 2012/7

N2 - Objective: To evaluate whether antioxidant supplements presumed to target specific cellular compartments affected cerebrospinal fluid (CSF) biomarkers. Design: Double-blind, placebo-controlled clinical trial. Setting: Academic medical centers. Participants: Subjects with mild to moderate Alzheimer disease. Intervention: Random assignment to treatment for 16 weeks with 800 IU/d of vitamin E (α-tocopherol) plus 500 mg/d of vitamin C plus 900 mg/d of α-lipoic acid (E/C/ALA); 400 mg of coenzyme Q 3 times/d; or placebo. Main Outcome Measures: Changes from baseline to 16 weeks in CSF biomarkers related to Alzheimer disease and oxidative stress, cognition (Mini-Mental State Examination), and function (Alzheimer's Disease Cooperative Study Activities of Daily Living Scale). Results: Seventy-eight subjects were randomized; 66 provided serial CSF specimens adequate for biochemical analyses. Study drugs were well tolerated, but accelerated decline in Mini-Mental State Examination scores occurred in the E/C/ALA group, a potential safety concern. Changes in CSF Aβ42, tau, and P-tau181 levels did not differ between the 3 groups. Cerebrospinal fluid F2-isoprostane levels, an oxidative stress biomarker, decreased on average by 19% from baseline to week 16 in the E/C/ALA group but were unchanged in the other groups. Conclusions: Antioxidants did not influence CSF biomarkers related to amyloid or tau pathology. Lowering of CSF F2-isoprostane levels in the E/C/ALA group suggests reduction of oxidative stress in the brain. However, this treatment raised the caution of faster cognitive decline, which would need careful assessment if longer-term clinical trials are conducted. Trial Registration: clinicaltrials.gov Identifier: NCT00117403.

AB - Objective: To evaluate whether antioxidant supplements presumed to target specific cellular compartments affected cerebrospinal fluid (CSF) biomarkers. Design: Double-blind, placebo-controlled clinical trial. Setting: Academic medical centers. Participants: Subjects with mild to moderate Alzheimer disease. Intervention: Random assignment to treatment for 16 weeks with 800 IU/d of vitamin E (α-tocopherol) plus 500 mg/d of vitamin C plus 900 mg/d of α-lipoic acid (E/C/ALA); 400 mg of coenzyme Q 3 times/d; or placebo. Main Outcome Measures: Changes from baseline to 16 weeks in CSF biomarkers related to Alzheimer disease and oxidative stress, cognition (Mini-Mental State Examination), and function (Alzheimer's Disease Cooperative Study Activities of Daily Living Scale). Results: Seventy-eight subjects were randomized; 66 provided serial CSF specimens adequate for biochemical analyses. Study drugs were well tolerated, but accelerated decline in Mini-Mental State Examination scores occurred in the E/C/ALA group, a potential safety concern. Changes in CSF Aβ42, tau, and P-tau181 levels did not differ between the 3 groups. Cerebrospinal fluid F2-isoprostane levels, an oxidative stress biomarker, decreased on average by 19% from baseline to week 16 in the E/C/ALA group but were unchanged in the other groups. Conclusions: Antioxidants did not influence CSF biomarkers related to amyloid or tau pathology. Lowering of CSF F2-isoprostane levels in the E/C/ALA group suggests reduction of oxidative stress in the brain. However, this treatment raised the caution of faster cognitive decline, which would need careful assessment if longer-term clinical trials are conducted. Trial Registration: clinicaltrials.gov Identifier: NCT00117403.

UR - http://www.scopus.com/inward/record.url?scp=84863798026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863798026&partnerID=8YFLogxK

U2 - 10.1001/archneurol.2012.85

DO - 10.1001/archneurol.2012.85

M3 - Article

C2 - 22431837

AN - SCOPUS:84863798026

VL - 69

SP - 836

EP - 841

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 7

ER -